1. Scrip
  2. >>R&D

CTI’s Vonjo Shows Potential In Anemic Myelofibrosis Patients, Promising Further Market Growth

Poses Threat To Other JAK Inhibitors

 
• By Ayisha Sharma

New data from anemic myelofibrosis patients showed the drug reduced transfusion dependence, which that could unlock a more sizeable portion of the market for CTI BioPharma.    

Person using key to unlock wooden figure
CTI Could Unlock A Bigger Chunk Of The Myelofibrosis Market • Source: Shutterstock

CTI BioPharma Corp.’s recently launched Vonjo can increase hemoglobin levels and reduce transfusion dependence in anemic myelofibrosis patients according to new data from the firm, which could support its expanded use.

Vonjo (pacritinib) first won a US accelerated approval for the treatment of myelofibrosis with severe thrombocytopenia early this year based on data from the 311-patient PERSIST-2 trial in which 29% of patients in a cohort with low platelet count saw reduction in spleen volume of at least 35% when treated with Vonjo, versus 3% of patients on best available therapy

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from R&D